Abstract 038: Association of Circulating Metabolites with Incident Heart Failure and its Subtypes in Multi-ethnic Populations

E Eun Hye Moon (UTHealth at Houston, Houston, Texas, United States) T Taryn Alkis (The University of Texas Health Science Center at Houston, Houston, Texas, United States) K Kai Luo M Megan Grove (UTHealth, Houston, Texas, United States) E Eric Boerwinkle C Clary Clish R Robert Gerszten M Michael and Jo Alice Hall (University of Mississippi Medical Center, Jackson, Mississippi, United States) L Lifang Hou S Scott Hutton (Metabolon, Inc, Morrisville, North Carolina, United States) R Robert Kaplan D Donald Lloyd-Jones (Framingham Center for Population and Prevention Science, Framingham, MA) B Bruce Psaty (University of Washington, Seattle, WA, USA.) L Laura Raffield C Carlos Rodriguez J Jerome Rotter (The Lundquist Institute, Torrance, California, United States) A Amil Shah (University of Texas Southwestern Medical Center, Dallas (A.S.).) S Sanjiv Shah (Northwestern University Feinberg School of Medicine, Chicago) K Kent Taylor (The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States) K Kari Wong V Vanessa Xanthakis V Vasan Ramachandran (The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States) B Bing Yu (College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry)

Abstract

Introduction: Metabolic dysregulation is recognized in heart failure (HF). A comprehensive assessment of circulating metabolites, specifically on HF subtypes, in multi-ethnic populations is limited. Hypothesis: We hypothesize that circulating metabolites are significantly associated with the risk of HF and have differential effects on HF subtypes. Methods: Circulating metabolites from seven studies in the Trans-Omics for Precision Medicine Program were analyzed among 21,398 HF-free participants (58% non-Whites, 58% women), from which 1,160 incident HF, 373 HF with reduced (HFrEF), and 439 HF with preserved ejection fraction (HFpEF) events were ascertained with an average of 11.5 years of follow up. Cox proportional hazard regressions were applied by the study, followed by random-effect meta-analyses, to produce metabolite HF associations. Over-representation analyses were performed to identify relevant metabolite pathways. Results: Out of 1,015 metabolites analyzed, 54 were significantly associated with incident HF (Bonferroni corrected p<0.05) after accounting for clinical risk factors. Eleven metabolic pathways were mapped; pentose and glucuronate interconversions and pyrimidine metabolism demonstrated over-representation (FDR<0.05). Most identified metabolites (93%) were positively associated with HF, and the strength of the associations persisted with further adjustment of kidney function. Thirteen metabolites showed consistent effects from all participating studies, and subtype analyses indicated that most metabolites were more strongly associated with HFpEF than HFrEF ( Figure ). For example, N-acetylputrescine, a precursor of γ-aminobutyric acid (GABA), and 4-acetamidobutanoate, a derivative of GABA, were associated with an increased risk of HFpEF but not HFrEF. Conclusions: We identified circulating metabolites associated with the risk of HF in multi-ethnic populations, highlighting the need to better understand the differential metabolic etiology of HFpEF compared to HFrEF.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (23)

E

Eun Hye Moon

UTHealth at Houston, Houston, Texas, United States

T

Taryn Alkis

The University of Texas Health Science Center at Houston, Houston, Texas, United States

K

Kai Luo

M

Megan Grove

UTHealth, Houston, Texas, United States

E

Eric Boerwinkle

C

Clary Clish

R

Robert Gerszten

M

Michael and Jo Alice Hall

University of Mississippi Medical Center, Jackson, Mississippi, United States

L

Lifang Hou

S

Scott Hutton

Metabolon, Inc, Morrisville, North Carolina, United States

R

Robert Kaplan

D

Donald Lloyd-Jones

Framingham Center for Population and Prevention Science, Framingham, MA

B

Bruce Psaty

University of Washington, Seattle, WA, USA.

L

Laura Raffield

C

Carlos Rodriguez

J

Jerome Rotter

The Lundquist Institute, Torrance, California, United States

A

Amil Shah

University of Texas Southwestern Medical Center, Dallas (A.S.).

S

Sanjiv Shah

Northwestern University Feinberg School of Medicine, Chicago

K

Kent Taylor

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

K

Kari Wong

V

Vanessa Xanthakis

V

Vasan Ramachandran

The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States

B

Bing Yu

College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry